Bleomycin sulfate CAS 9041-93-4
Introduction：Basic information about Bleomycin sulfate CAS 9041-93-4, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
Bleomycin sulfate Basic information
| Product Name: | Bleomycin sulfate |
| Synonyms: | BLEOMYCIN SULFATE CELL CULTURE TESTED;BLEOMYCIN SULFATE, BPC;BLEOMYCIN SULFATE FROM STREPTOMYCES VERT ICILLUS, LYOPH.;BLEOMYCIN SULFATE FROM STREPTOMYCES VERTICILLUS 0 TO 5 °C;Blocamicina;BLEMOYCIN SULFATE;3-[[2-[2-[2-[2-[4-[2-[6-Amino-2-[1-(2-amino-2-carbamoyl-ethyl)amino-2-carbamoyl-ethyl]-5-methyl-pyrimidin-4-yl]carbonylamino-3-[3-[4-carbamoyloxy-3,5-dihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]oxy-3-(3H-imidazol-4-yl)propanoyl]amino-3-hydroxy-2-methyl-pentanoyl]amino-3-hydroxy-butanoyl]aminoethyl]-1,3-thiazol-4-yl]-1,3-thiazol-4-yl]carbonylamino]propyl-dimethyl-sulfonium hydrogen sulfate;Bleomycin Sulfate, Blenoxane |
| CAS: | 9041-93-4 |
| MF: | C110H168N34O46S7 |
| MW: | 2927.17 |
| EINECS: | 232-925-2 |
| Product Categories: | BLENOXANE;antibiotic;Intermediates & Fine Chemicals;Pharmaceuticals;Carbohydrates & Derivatives;Sulfur & Selenium Compounds;Active Pharmaceutical Ingredients;UVCBs-biological;API;Inhibitors;APIs |
| Mol File: | 9041-93-4.mol |
Bleomycin sulfate Chemical Properties
| Melting point | 200-204°C (dec.) |
| storage temp. | 2-8°C |
| solubility | H2O: 20 mg/mL |
| form | powder |
| color | white |
| Water Solubility | Soluble in water or DMSO |
| Merck | 14,1318 |
| Stability: | Stable for 1 year from the date of purchase. Solutions in distilled water may be stored at -20°C for up to 3 months. |
| InChIKey | OOXTWFJZZAJGKA-YWZNXBAZNA-N |
| CAS DataBase Reference | 9041-93-4(CAS DataBase Reference) |
Safety Information
| Hazard Codes | T,Xi |
| Risk Statements | 46-40-36/37/38-63 |
| Safety Statements | 53-36/37-45-36-26 |
| WGK Germany | 3 |
| RTECS | EC5991990 |
| F | 10 |
| HS Code | 2941906000 |
| Storage Class | 6.1C - Combustible acute toxic Cat.3 toxic compounds or compounds which causing chronic effects |
| Hazard Classifications | Carc. 2 Muta. 1B Repr. 2 |
| Description | Bleomycin sulfate (9041-93-4) coordinates with metals producing reactive oxygen species which causes oxidative damage to DNA1?and RNA2. Induces double-strand DNA damage.3?Commonly used to induce lung fibrosis in animal disease models.4,5?Anticancer agent in clinical use.6 |
| Chemical Properties | White Powder |
| Uses | Bleomycin sulfate binds to DNA, and can inhibit DNA synthesis and causes scission of DNA. Cleaves DNA, requires binding to oxygen and a metal ion, such as copper or iron. Able to cleave RNA, but at less and more selective degree. Also reported to induce and regulate apoptosis in a variety of cells, and inhibit tumor angiogenesis. |
| Mechanism of action | Bleomycin is a complex of 11 glycopeptide antitumor antibiotics originally isolated from Streptomyces verticillus in 1972. The dominant components of the complex are bleomycin A2 and B2, which typically represent >90% of the total weight. Bleomycins have found clinical application in the treatment of a range of tumors. Bleomycins act by intercalation of DNA and RNA. In the presence of oxygen and metal ions, notably copper and iron, bleomycins form a pseudo-enzyme that induces DNA cleavage. |
| Brand name | Blenoxane (Bristol-Myers Squibb). |
| General Description | Bleomycin occurs as a white powder and is available in 15-and 30-U vials for reconstitution in water. It may be givenintravenously, intramuscularly, or subcutaneously. It is used in the treatment of squamous cell carcinoma of the headneck, cervix, penis, and vulva. It is also used in Hodgkin’sand non-Hodgkin’s lymphoma as well as testicular carcinoma.Unlabeled uses include the treatment of mycosis fungoides,osteosarcoma, and AIDS-related Kaposi sarcoma. |
| Biochem/physiol Actions | Bleomycin sulfate binds to DNA, causes ssDNA scission at specific base sequences and inhibits DNA synthesis. This inhibitory action requires bleomycin to bind oxygen and a metal ion. It can also cleave RNA, to a lesser degree but more selectively. It acts as an inducer and regulator of apoptosis and inhibits tumor angiogenesis. |
| Clinical Use | Bleomycin is used IV in the palliative treatment of squamous cell head and neck cancers, testicular and other genital carcinomas, and Hodgkin's and non-Hodgkin's lymphoma. |
| Side effects | It is excreted via the kidneys, and serum concentrations of active drug are increased in patients with renal disease. The elimination half-life can rise from 2 to 4 hours to more than 20 hours in renal failure, resulting in significant toxicity, especially pulmonary toxicity. |
| Veterinary Drugs and Treatments | Bleomycin has occasionally been used as adjunctive treatment oflymphomas, squamous cell carcinomas, teratomas, and nonfunctionalthyroid tumors in both dogs and cats. Recent work has demonstratedthat bleomycin may be promising for intralesional treatmentfor a variety of localized tumors with or without concomitantelectropermeabilization. |
| target | UT-SCC-129 cells |
| References | [1] DAVID H. PETERING William E A Robert W Byrnes. The role of redox-active metals in the mechanism of action of bleomycin[J]. Chemico-Biological Interactions, 1990, 73 2: Pages 133-182. DOI:10.1016/0009-2797(90)90001-4 [2] A. HÜTTENHOFER. Cleavage of tRNA by Fe(II)-bleomycin.[J]. The Journal of Biological Chemistry, 1992, 81 1: 24471-24475. DOI:10.1016/s0021-9258(18)35790-9 [3] KYUNG YONG LEE. ASF1a Promotes Non-homologous End Joining Repair by Facilitating Phosphorylation of MDC1 by ATM at Double-Strand Breaks.[J]. Molecular Cell, 2017, 68 1: 61-75.e5. DOI:10.1016/j.molcel.2017.08.021 [4] YAN XIE. Upregulation of RGS2: a new mechanism for pirfenidone amelioration of pulmonary fibrosis.[J]. Respiratory Research, 2016: 103. DOI:10.1186/s12931-016-0418-4 [5] MINORU INOMATA. Pirfenidone inhibits fibrocyte accumulation in the lungs in bleomycin-induced murine pulmonary fibrosis.[J]. Respiratory Research, 2014: 16. DOI:10.1186/1465-9921-15-16 [6] TOSHIKO TANAKA. Increased glutathione level is not involved in enhanced bleomycin sensitivity in cisplatin-resistant 2780CP cells.[J]. Anticancer research, 2008, 28 5A: 2663-2668. |
Bleomycin sulfate Preparation Products And Raw materials
| Raw materials | Potassium Phosphate Monobasic-->Zinc sulphate-->Disodium edetate dihydrate-->streptomyces avermifilis-->Dithizone-->Cation exchange resin,weak acidic acrylic acid |
| Preparation Products | PEPLOMYCIN |
